MDT Medtronic plc
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1613103 · Fiscal year ends 04/24
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY12.3%
TTM EPS YoY12.2%
Revenue 3-yr CAGR6.0%
Net income 3-yr CAGR13.1%
Margins
Gross margin65.0%
Operating margin18.1%
Net margin13.9%
FCF margin16.3%
EBITDA margin23.5%
Returns
ROE10.7%
ROA5.7%
ROIC (approx.)7.1%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets45.5%
Debt / equity0.56x
Current ratio2.07x
Interest coverage9.37x
Cash quality & payout
Operating cash flow / net income1.54x
Accruals ratio-3.0%
Payout ratio69.8%
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-07-31 | 2026Q4*2026-04-24 | 2026Q32026-01-23 | 2026Q22025-10-24 | 2026Q12025-07-25 | 2025Q4*2025-04-25 | 2025Q32025-01-24 | 2025Q22024-10-25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.76B | $9.81B | $9.02B | $8.96B | $8.58B | $8.93B | $8.29B | $8.40B |
| Cost of revenue | $3.42B | $3.40B | $3.26B | $3.06B | $3.00B | $3.15B | $2.78B | $2.95B |
| Gross profit | $6.34B | $6.41B | $5.76B | $5.90B | $5.58B | $5.78B | $5.51B | $5.46B |
| R&D expense | $771.00M | $671.00M | $722.00M | $754.00M | $726.00M | $684.00M | $675.00M | $697.00M |
| SG&A expense | $3.20B | $3.06B | $2.96B | $2.96B | $2.81B | $2.72B | $2.72B | $2.76B |
| Operating income | $1.76B | $1.87B | $1.46B | $1.69B | $1.45B | $1.44B | $1.65B | $1.59B |
| Interest expense | $186.00M | $176.00M | $181.00M | $181.00M | $176.00M | $174.00M | $179.00M | $209.00M |
| Pretax income | $1.77B | $1.83B | $1.40B | $1.60B | $1.30B | $1.26B | $1.54B | $1.56B |
| Income tax | $289.00M | $575.00M | $254.00M | $215.00M | $255.00M | $199.00M | $237.00M | $281.00M |
| Net income | $1.47B | $1.24B | $1.14B | $1.37B | $1.04B | $1.06B | $1.29B | $1.27B |
| EBITDA | $2.49B | $2.59B | $1.77B | $1.97B | $2.19B | $2.28B | $1.91B | $1.86B |
| EPS (basic) | 1.15 | — | 0.89 | 1.07 | 0.81 | — | 1.01 | 0.99 |
| EPS (diluted) | 1.14 | — | 0.89 | 1.07 | 0.81 | — | 1.01 | 0.99 |
| Dividends declared per share | 0.72 | 0.71 | 0.71 | 0.71 | 0.71 | 0.70 | 0.70 | 0.70 |
| Weighted avg. shares (diluted) | 1.29B | — | 1.29B | 1.29B | 1.29B | — | 1.29B | 1.29B |
| Banking | ||||||||
| Net interest income | $102.00M | $89.00M | $85.00M | $89.00M | $120.00M | $147.00M | $114.00M | $137.00M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.69B | $1.95B | $1.15B | $1.28B | $1.27B | $2.22B | $1.24B | $1.39B |
| Short-term investments | $7.13B | $7.27B | $7.24B | $7.04B | $6.85B | $6.75B | $6.68B | $6.59B |
| Receivables | $6.36B | $6.64B | $6.36B | $6.39B | $6.26B | $6.51B | $6.12B | $6.26B |
| Inventory | $6.21B | $5.95B | $6.31B | $6.16B | $5.89B | $5.48B | $5.61B | $5.48B |
| Current assets | $24.39B | $24.79B | $24.07B | $24.00B | $23.22B | $23.81B | $22.51B | $22.44B |
| PP&E, net | $7.47B | $7.42B | $7.18B | $7.16B | $7.01B | $6.84B | $6.59B | $6.44B |
| Goodwill | $43.19B | $42.59B | $41.89B | $41.81B | $42.01B | $41.74B | $40.82B | $41.16B |
| Intangibles | $10.24B | $10.15B | $10.34B | $10.77B | $11.22B | $11.67B | $12.18B | $12.42B |
| Total assets | $93.31B | $93.03B | $91.48B | $91.35B | $90.97B | $91.68B | $89.97B | $90.04B |
| Current liabilities | $11.80B | $11.66B | $9.49B | $9.94B | $11.53B | $12.88B | $11.84B | $12.20B |
| Short-term debt | $2.54B | $1.79B | $191.00M | $1.42B | $2.43B | $2.87B | $2.62B | $3.72B |
| Long-term debt | $25.62B | $26.17B | $27.88B | $27.68B | $26.18B | $25.64B | $23.98B | $24.61B |
| Total debt | $28.15B | $27.96B | $28.07B | $29.10B | $28.61B | $28.52B | $26.61B | $28.33B |
| Total liabilities | $42.46B | $42.96B | $42.29B | $42.49B | $42.84B | $43.42B | $40.36B | $41.33B |
| Shareholders' equity | $50.23B | $49.46B | $48.98B | $48.65B | $47.89B | $48.02B | $49.39B | $48.49B |
| Net debt | $26.46B | $26.01B | $26.92B | $27.82B | $27.34B | $26.30B | $25.37B | $26.93B |
| Shares outstanding | 1.28B | 1.28B | 1.28B | 1.28B | 1.28B | 1.28B | 1.28B | 1.28B |
| Cash flow statement | ||||||||
| Operating cash flow | $1.79B | $2.57B | $2.74B | $925.00M | $1.09B | $2.53B | $2.57B | $958.00M |
| Capital expenditure | $503.00M | $488.00M | $444.00M | $468.00M | $504.00M | $459.00M | $476.00M | $404.00M |
| Free cash flow | $1.29B | $2.08B | $2.30B | $457.00M | $584.00M | $2.07B | $2.10B | $554.00M |
| Investing cash flow | -$1.62B | -$917.00M | -$816.00M | -$482.00M | -$719.00M | -$490.00M | -$843.00M | -$345.00M |
| Financing cash flow | -$343.00M | -$888.00M | -$2.09B | -$395.00M | -$1.38B | -$1.34B | -$1.75B | -$534.00M |
| Depreciation & amortization | $729.00M | $716.00M | $308.00M | $282.00M | $748.00M | $840.00M | $268.00M | $262.00M |
| Stock-based compensation | $125.00M | $95.00M | $95.00M | $182.00M | $86.00M | $89.00M | $98.00M | $159.00M |
| Dividends paid | $921.00M | $908.00M | $911.00M | $910.00M | $910.00M | $897.00M | $897.00M | $897.00M |
| Share buybacks | $267.00M | $435.00M | $105.00M | $372.00M | $123.00M | $274.00M | $181.00M | $288.00M |
Free plan shows the latest 8 periods; Pro shows all 53 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.